Pathological complete response induced by first-line chemotherapy with single agent docetaxel in a patient with advanced non small cell lung cancer
Ferdinando Riccardi(Ospedale Antonio Cardarelli), Giacomo Cartenì(Ospedale Antonio Cardarelli), Carlo Buonerba(CTO Andrea Alesini), Guglielmo Monaco(Ospedale Antonio Cardarelli), Mimma Rizzo(University of Pavia), Roberto Di Monaco, Florinda Scognamiglio, Giuseppe Di Lorenzo(Saint Camillus International University of Health and Medical Sciences), Sarah Scagliarini(Ospedale Antonio Cardarelli), Marilena Di Napoli(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale")
Cited by 3
Related Papers
Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab
|Clinical Cancer Research|2019|240
First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial
|Journal of Clinical Oncology|2012|234
Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis
|Annals of Oncology|2009|205
Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial
|Journal of Clinical Oncology|2017|186
Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumors Retrospective Study
|The Journal of Clinical Endocrinology & Metabolism|2019|180